Ya Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ya Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Banghua Liao
Department of Urology and Institute of Urology (Laboratory of Reconstructive Urology) West China Hospital, Sichuan University Chengdu PR China
3 shared publicationsTianyue Li
Department of Urology and Institute of Urology (Laboratory of Reconstructive Urology) West China Hospital, Sichuan University Chengdu PR China
3 shared publications- Deyi Luo
Department of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Jiawei Chen
Department of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Jingwen Wei
Department of Urology and Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan People's Republic of China
2 shared publications - Kunjie Wang
Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in The Journal of Pathology
Gut microbiota‐derived tryptophan metabolite attenuates calcium oxalate nephropathy by suppressing renal tubular cell apoptosis through the AhR – SOCS3 – STAT1 axis
Calcium oxalate (CaOx) nephropathy is a highly prevalent urological disease worldwide. Gut microbiota dysbiosis and host metabolic dysregulation are recognized as pivotal drivers in disease pathogenesis, yet the underlying mechanisms remain incompletely understood. In this study, by integrating metagenomics and metabolomics, we identified dysregulation of tryptophan metabolites in patients with CaOx nephrolithiasis, with microbiota‐derived indole‐3‐propionic acid (IPA) as the most discriminatory differential metabolite. Oral IPA supplementation markedly reduced renal CaOx crystal deposition and tubular injury in a CaOx nephropathy murine model. Mechanistically, IPA activated the aryl hydrocarbon receptor (AhR), which translocated to the nucleus and transcriptionally upregulated suppressor of cytokine signaling 3 (SOCS3)—a negative regulator of signal transducer and activator of transcription 1 (STAT1)—thereby suppressing STAT1 phosphorylation, alleviating oxalate‐induced tubular cell injury and apoptosis, and inhibiting CaOx crystal deposition. Our findings identify tryptophan metabolite alteration as a critical metabolic signature of CaOx nephropathy and demonstrate that microbiota‐derived IPA attenuates oxalate‐induced renal tubular cell injury and apoptosis via the AhR–SOCS3–STAT1 axis. © 2026 The Pathological Society of Great Britain and Ireland.
- 9 October 2026
- Published by Wiley in The Journal of Pathology
Gut microbiota‐derived tryptophan metabolite attenuates calcium oxalate nephropathy by suppressing renal tubular cell apoptosis through the AhR – SOCS3 – STAT1 axis
Calcium oxalate (CaOx) nephropathy is a highly prevalent urological disease worldwide. Gut microbiota dysbiosis and host metabolic dysregulation are recognized as pivotal drivers in disease pathogenesis, yet the underlying mechanisms remain incompletely understood. In this study, by integrating metagenomics and metabolomics, we identified dysregulation of tryptophan metabolites in patients with CaOx nephrolithiasis, with microbiota‐derived indole‐3‐propionic acid (IPA) as the most discriminatory differential metabolite. Oral IPA supplementation markedly reduced renal CaOx crystal deposition and tubular injury in a CaOx nephropathy murine model. Mechanistically, IPA activated the aryl hydrocarbon receptor (AhR), which translocated to the nucleus and transcriptionally upregulated suppressor of cytokine signaling 3 (SOCS3)—a negative regulator of signal transducer and activator of transcription 1 (STAT1)—thereby suppressing STAT1 phosphorylation, alleviating oxalate‐induced tubular cell injury and apoptosis, and inhibiting CaOx crystal deposition. Our findings identify tryptophan metabolite alteration as a critical metabolic signature of CaOx nephropathy and demonstrate that microbiota‐derived IPA attenuates oxalate‐induced renal tubular cell injury and apoptosis via the AhR–SOCS3–STAT1 axis. © 2026 The Pathological Society of Great Britain and Ireland.
- Open Access
- 14 December 2025
- Published by Wiley in MedComm – Oncology
- Vol. 4 (4)
Crosstalk Between Cancer‐Associated Fibroblasts and Immune Cells: Mechanisms and Therapeutic Implications
Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment (TME) interact with multiple immune cells, such as T cells, macrophages, neutrophils, and other immune cells, to display both antitumor or protumor effects. Despite enormous progress in immunotherapy, the CAF‐associated resistance of immunotherapy is still urgent to be solved. In this review, we summarize the origins and heterogeneity of CAFs in the TME, including the subpopulations of CAFs and their biological function. Then we discuss the communications between CAFs and tumor‐associated macrophages, T lymphocytes, tumor‐associated neutrophils, and other immune cells. CAFs cannot only recruit immune cells in the TME, but also trigger polarization, proliferation, infiltration of immune cells, thereby promoting tumor progression. Inversely, some immune cells promote the recruitment, transdifferentiation, and proliferation of CAFs. We also focus on the current progress in therapeutic strategies targeting CAF‐elimination, CAF‐reprograming, downstream signaling blockade, and CAF‐induced extracellular matrix barrier elimination to enhance the efficacy of immunotherapy and related clinical trials. Overall, we aim to provide the conceptions of CAF‐immunocyte crosstalk in the TME and application of immunotherapy, paving the way for the development of precise and individualized strategies through clarifying the interaction between CAFs and immunocytes.
- 14 December 2025
- Published by Wiley in MedComm – Oncology
- Vol. 4 (4)
Open AccessCrosstalk Between Cancer‐Associated Fibroblasts and Immune Cells: Mechanisms and Therapeutic Implications
Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment (TME) interact with multiple immune cells, such as T cells, macrophages, neutrophils, and other immune cells, to display both antitumor or protumor effects. Despite enormous progress in immunotherapy, the CAF‐associated resistance of immunotherapy is still urgent to be solved. In this review, we summarize the origins and heterogeneity of CAFs in the TME, including the subpopulations of CAFs and their biological function. Then we discuss the communications between CAFs and tumor‐associated macrophages, T lymphocytes, tumor‐associated neutrophils, and other immune cells. CAFs cannot only recruit immune cells in the TME, but also trigger polarization, proliferation, infiltration of immune cells, thereby promoting tumor progression. Inversely, some immune cells promote the recruitment, transdifferentiation, and proliferation of CAFs. We also focus on the current progress in therapeutic strategies targeting CAF‐elimination, CAF‐reprograming, downstream signaling blockade, and CAF‐induced extracellular matrix barrier elimination to enhance the efficacy of immunotherapy and related clinical trials. Overall, we aim to provide the conceptions of CAF‐immunocyte crosstalk in the TME and application of immunotherapy, paving the way for the development of precise and individualized strategies through clarifying the interaction between CAFs and immunocytes.
- Open Access
- 24 January 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1545
Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials
Background: The impact of fibroblasts on the immune system provides insight into the function of fibroblasts. In various tissue microenvironments, multiple fibroblast subtypes interact with immunocytes by secreting growth factors, cytokines, and chemokines, leading to wound healing, fibrosis, and escape of cancer immune surveillance. However, the specific mechanisms involved in the fibroblast‐immunocyte interaction network have not yet been fully elucidated.Main body and conclusion: Therefore, we systematically reviewed the molecular mechanisms of fibroblast‐immunocyte interactions in fibrosis, from the history of cellular evolution and cell subtype divisions to the regulatory networks between fibroblasts and immunocytes. We also discuss how these communications function in different tissue and organ statuses, as well as potential therapies targeting the reciprocal fibroblast‐immunocyte interplay in fibrosis. A comprehensive understanding of these functional cells under pathophysiological conditions and the mechanisms by which they communicate may lead to the development of effective and specific therapies targeting fibrosis.
- 24 January 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1545
Open AccessCrosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials
Background: The impact of fibroblasts on the immune system provides insight into the function of fibroblasts. In various tissue microenvironments, multiple fibroblast subtypes interact with immunocytes by secreting growth factors, cytokines, and chemokines, leading to wound healing, fibrosis, and escape of cancer immune surveillance. However, the specific mechanisms involved in the fibroblast‐immunocyte interaction network have not yet been fully elucidated.Main body and conclusion: Therefore, we systematically reviewed the molecular mechanisms of fibroblast‐immunocyte interactions in fibrosis, from the history of cellular evolution and cell subtype divisions to the regulatory networks between fibroblasts and immunocytes. We also discuss how these communications function in different tissue and organ statuses, as well as potential therapies targeting the reciprocal fibroblast‐immunocyte interplay in fibrosis. A comprehensive understanding of these functional cells under pathophysiological conditions and the mechanisms by which they communicate may lead to the development of effective and specific therapies targeting fibrosis.